Skip to main content
Psychopharmacology Bulletin All Volumes & Issues VOL 37 No. 4 Continuation Treatment of...
EVIDENCE-BASED MEDICINE

Continuation Treatment of Chronic Depression: A Comparison of Nefazodone, Cognitive Behavioral Analysis System of Psychotherapy, and Their Combination

Psychopharmacology Bulletin 37(4) :73-87 , 2004/02/27

Abstract

Little is known about the relative benefits of psychotherapy, medication, and combined treatment as continuation therapies for chronic forms of major depressive disorder (MDD) after a positive response to acute treatment. We hypothesize that combined treatment would demonstrate superior continuation phase outcomes compared to either monotherapy, as evidenced by lower relapse rates and greater rates of improvement from partial to full remission. We report 16-week continuation phase outcomes for 324 patients who had participated in either the acute phase of a randomized multicenter trial of nefazodone, Cognitive Behavioral Analysis System of Psychotherapy (CBASP), or combination therapy (COMB) for chronic forms of MDD. Patients entering the continuation phase had either fully or partially remitted after 12 weeks of acute phase treatment. The primary

Access This Article

Choose an access option below to view the full article.

Subscriber Access

If you or your institution has a subscription, log in to access this article.

Log In

Purchase Article

Buy single-article access with a one-time purchase.

$30.00
Add to Cart

How to Cite

James H. Kocsis, MD, A. John Rush, MD, John C. Markowitz, MD, Frances E. Borian, RN, MBA, David L. Dunner, MD, Lorrin M. Koran, MD, Daniel N. Klein, PhD, Madhukar H. Trivedi, MD, Bruce Arnow, PhD, Gabor Keitner, MD, Susan G. Kornstein, MD, and Martin B. Keller, MD. Continuation Treatment of Chronic Depression: A Comparison of Nefazodone, Cognitive Behavioral Analysis System of Psychotherapy, and Their Combination. Psychopharmacology Bulletin. 2004/02/27; 37(4):73-87.